COMPOSITION:

Each film-coated tablet contains:

ATORNET – 5
Each film-coated tablet contains:
Atorvastatin calcium equivalent to Atorvastatin … 5mg

ATORNET – 10 
Each film-coated tablet contains:
Atorvastatin calcium equivalent to Atorvastatin … 10 mg

ATORNET-20
Each film-coated tablet contains:
Atorvastatin calcium equivalent to Atorvastatin … 20mg

DESCRIPTION: Atorvastatin is a selective competitive inhibitor of 3-hydroxy-3-methyl-glutaryl- coenzyme A (HMG-CoA) reductase enzyme. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the synthesis of cholesterol.
In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic low density lipoprotein (LDL) receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles. Atorvastatin reduces LDL-cholesterol (LDL-C) in some patients with homozygous familial hypercholesterolemia, a population that rarely responds to other lipid-lowering medication(s).
The primary site of action of HMG-CoA reductase inhibitors is the liver. Inhibition of cholesterol synthesis in the liver leads to the upregulation of LDL-receptors and an increase in LDL- catabolism. There is also some reduction of LDL production as a result of inhibition of hepatic synthesis of very-low-density lipoprotein (VLDL), the precursor of LDL-C. Atorvastatin reduces total cholesterol, LDL-C, and apo B in patients with homozygous and heterozygous familial hypercholesterolemia, non-familial forms of hypercholesterolemia and mixed dyslipidemias. Atorvastatin also reduces VLDL-cholesterol (VLDL-C) and triglycerides and produces variable increases in high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1. Atorvastatin reduces total cholesterol, LDL-C, VLDL-C, apo B, triglycerides, and non-HDL-C, and increases HDL-C in patients with isolated hypertriglyceridemia. Atorvastatin also reduces intermediate-density lipoprotein cholesterol (IDL-C) in patients with dysbetalipoproteinemia. Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. Drug dosage rather than systemic drug concentration correlates better.

INDICATIONS:
ATORNET is an HMG-CoA reductase inhibitor indicated as an adjunct therapy to diet to:

  • Reduce the risk of MI, stroke, revascularization procedures, and angina in adult patients without CHD, but with multiple risk factors.
  • Reduce the risk of MI and stroke in adult patients with type 2 diabetes without CHD, but with multiple risk factors.
  • Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in adult patients with CHD.
  • Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDLC in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.
  • Reduce elevated TG in adult patients with hypertriglyceridemia and primary dysbetalipoproteinemia.
  • Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH).
  • Reduce elevated total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) after failing an adequate trial of diet therapy.

DOSAGE: As directed by the physician

CONTRAINDICATIONS:
Hypersensitivity to any component of this medication Active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal Pregnancy and Lactation.